Diffusion weighted imaging of prostate cancer xenografts: comparison of bayesian modeling and independent least squares fitting

Parisa Movahedi¹, Hanne Hakkarainen², Harri Merisaari¹, Heidi Liljenbäck¹, Helena Virtanen¹, Hannu Juhani Aronen¹, Heikki Minn¹, Matti Poutanen¹, Anne Roivainen¹, Timo Liimatainen², and Ivan Jambor¹

¹University of Turku, Turku, Finland, ²A.I. Virtanen Institute for Molecular Sciences, Kuopio, Finland

Synopsis

Tumor growth in mice preclinical prostate cancer model (human prostate cancer cells, PC-3) was followed for 4 weeks by weekly DWI in control group (n=10) and treatment group (n=9) receiving Docetaxel. DWI data sets were acquired using 15 b-values in the range of 0-500s/mm² and 12 b-values the range of 0-2000 s/mm². The DWI signal decays were fitted using monoexponential, biexponential, kurtosis and stretched exponential models/functions. Bayesian shrinkage prior method and independent least squares fitting have been applied and fitting quality evaluated by corrected Akaike Information Criteria. Bayesian modeling improved quality of DWI parametric maps derived using high b-value DWI data sets. Our result does not support the use of biexponential, kurtosis and stretched exponential models/functions for low b value DWI data sets of PC-3 mice preclinical prostate cancer model.

Purpose

To evaluate different mathematical functions/models for DWI of mice preclinical prostate cancer model (human prostate cancer cells, PC-3) using Bayesian shrinkage prior method and independent least squares fitting.

Methods

One million PC-3 (Anticancer Inc., USA) human prostate cancer cells were inoculated subcutaneously in immunodeficient mice (n=11, HSD: Athymic Nude Foxn 1nu, Harlan Laboratories, Indianapolis, IN, USA). All animal handling was conducted in accordance with the local ethics committee for the use and care of laboratory animals and the institutional animal care policies, which fully meet the requirements as defined in the U.S. National Institutes of Health guidelines on animal experimentation. The mice were divided into 2 groups: 1. control group (n=10), 2. treatment group (n=9). The treatment group received Docetaxel (Docetaxel, Actavis, Espoo, Finland) given once a week for three weeks as i.p. injections. The dose was 15mg/kg. Tumor growth in both of the groups was followed by weekly MRI examinations performed using a 7T MR scanner (7T Pharmascan, Bruker GmbH, Ettlingen, Germany) and a 72 mm volume transmitter (Bruker GmbH) and 10 mm surface receiver coil (Bruker GmbH). Multislice T2-weighted anatomical images covering the whole tumor area were obtained (TR/TE 2500 ms/33 ms, field of view (FOV) = 30×30 mm2, matrix size 256×256 , 15 slices) to localize a slice with maximum tumor diameter for DWI measurements. Diffusion weighted single shot spin-echo echo planar imaging was applied with the parameters: TR/TE 3750/25.3 (low b-value set) 3000/30 ms (high b-

value set), FOV 3×1.5 cm2, matrix 128×64 , slice thickness 1 mm, three orthogonal diffusion directions, and two different sets of b-values: low b-value set (15 b-values in total): 0, 2, 4, 6, 9, 12, 14, 18, 23, 25, 28, 50, 100, 300, 500 s/mm2, and high b-value set (12 b-values in total): 0, 100, 300, 500, 700, 900, 1100, 1300, 1500, 1700, 1900, 2000 s/mm2. For further analysis, the mean value of the signal from three directions was calculated. The following four mathematical functions/models were applied to the DWI signal obtained using low and high b-values:

1. Mono-exponential model (1):

$$S(b) = S_0 e^{-bADC_m}S(b) = S_0 e^{-bADC_m}S(b)$$

Eq. 1 2. Stretched exponential model (2):

 $S(b) = S_0 e^{-bADC_\alpha}S(b) = S_0 e^{-bADC_\alpha}$

Eq. 2 3. Kurtosis model (3):

 $S(b) = S_0(e - bADC_{k+1/6b_2ADC_{2k}K})S(b) = S_0(e - bADC_{k+1/6b_2ADC_{k2}K})$

Eq. 3

4a. Bi-exponential model for low b-values (4):

$$S(b) = S_0(f_{e-bD_p} + (1-f)e_{-bD_f})S(b) = S_0(f_{e-bD_f} + (1-f)e_{-bD_f})S(b) = S_0(f_{e-$$

Eq. 4

4b. Bi-exponential model for high b-values (5):

$$S(b) = S_0(f_{e-bD_f} + (1-f)e_{-bD_s})S(b) = S_0(f_{e-bD_f} + (1-f)e_{-bD_s})$$

Eq. 5

The DWI signal decay of each individual voxel has been fitted using four mathematical models, as described above, to generate parametric maps of the parameters. The fitting procedure has been performed using the Levenberg–Marquardt algorithm in Python programming language and following multiple initialization values to prevent local minima in the fitting procedure. Furthermore, all of the parameters except of the Mono-exponential model's parameter (ADCm) have been fitted by a Bayesian shrinkage method (6). The Bayesian shrinkage prior (BSP) model takes the estimated parameters from least squares fit as a prior distribution of the region of interest, jointly estimating the voxel-wise parameters based on the ROI distribution. The Markove chain algorithm utilizing Gibbs sampling with Metropolis-Hastings updates for each voxel parameter. The tumor area was manually delineated on T2-weighted anatomical images and the regions of interest (ROIs) were transferor to the corresponding parametric images. Corrected Akaike information criteria difference (AICc) (7) was used to evaluate fitting quality.

Results

The use of Bayesian shrinkage method resulted in reduced parameter variation (Figure 1) and smoother parametric maps (Figure 2) which could be attributed to reduced estimation uncertainty of each model. Bayesian shrinkage method resulted in approximately 20% and 40% increase in root measure error of the least square fitting procedure in high and low b-value data sets, respectively (Figure 3). In majority of voxels (above 50%) stretched exponential, kurtosis and bi-exponential models fitted DWI data obtained using high b-values better than the mono-exponential model based on AICc (Figure 4). The kurtosis model was preferred over the stretched exponential model in average in approximately ~70% of voxels. In contrast, stretched exponential, kurtosis and bi-exponential models were not preferred over the monoexponential model in DWI data obtained using low b-values (Figure 5).

Conclusion

Bayesian modeling improved quality of DWI parametric maps derived using high b-value DWI data sets. Our result does not support the use of biexponential, kurtosis and stretched exponential models/functions for low b value DWI data sets of PC-3 mice preclinical prostate cancer model.

Acknowledgements

No acknowledgement found.

References

1. Stejskal EO. Use of spin echoes in a pulsed magnetic-field gradient to study restricted diffusion and flow. J Chem Phys 1965;43;3597–3603

2. Kopf M, Corinth C, Haferkamp O, Nonnenmacher TF. Anomalous diffusion of water in biological tissues. Biophys J 1996; 70:2950-2958.

3. Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 2010; 23:698-710.

4. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168:497-505.

5. Mulkern RV, Gudbjartsson H, Westin CF, et al. Multi-component apparent diffusion coefficients in human brain. NMR Biomed 1999; 12:51-62.

6. Orton MR, Collins DJ, Koh DM, Leach MO. Improved intravoxel incoherent motion analysis of diffusion weighted imaging by data driven Bayesian modeling. Magn Reson Med 2014; 71:411-420.

7. Akaike H. Information theory as an extension of the maximum likelyhood principle. In: Petrov BN, Csaki F, editors. Second International Symposium on Information Theory. Budapest: Akademiai Kaido; 1973. p 267–281.

Figures



Box plots of voxel values derived using independent least squares fitting (A, B, C, D, I, J, K, L) and bayesian shrinkage method (F, G, H, M, N, O, P) for high b values data sets of control group. ADCm parameter (A) was estimated only using independent least squares fitting. The box extends from the 25th to 75th percentiles while the error bars extend from minimal to maximal values.



Parametric maps using independent least squares fitting, LSG fit, (A, B, D, F, H, J, L, N) and Bayesian shrinkage method, BSP Fit, (C, E, G, I, K, M, O) for high b value data sets of control group mice in week 3. ADCm parameter (A) was estimated only using independent least squares fitting.

| | Biexponential | Kurtosis | Stretched |
|---------------------------------|---------------|----------|-----------|
| Control Group (high b-values) | 20% | 25% | 19% |
| Treatment Group (high b-values) | 21% | 23% | 18% |
| Control Group (low b-values) | 23% | 49% | 33% |
| Treatment Group (low b-values) | 43% | 32% | 36% |

Median percentage value of root mean square error increase of the bayesian shrinkage method over independent least squares fitting.

| Control group (High b-values) | week1 | week2 | week3 | week4 |
|--|--|---|--|---|
| Stretched vs. Mono | 100% | 99% | 100% | 99% |
| Kurtosis vs. Mono | 100% | 100% | 99% | 99% |
| Biexp vs. Mono | 99% | 99% | 100% | 97% |
| Kurtosis vs. Stretched | 70% | 73% | 71% | 76% |
| Biexp vs. Stretched | 80% | 76% | 64% | 59% |
| Biexp vs. Kurtosis | 57% | 37% | 26% | 13% |
| Stretched (Bayesian) vs. Mono | 97% | 91% | 94% | 89% |
| Kurtosis (Bayesian) vs. Mono | 98% | 97% | 97% | 95% |
| Biexp (Bayesian) vs. Mono | 100% | 99% | 100% | 99% |
| Kurtosis (Bayesian) vs. Stretched (Bayesian) | 63% | 67% | 66% | 67% |
| Biexp (Bayesian) vs. Stretched (Bayesian) | 78% | 72% | 62% | 62% |
| Biexp (Bayesian) vs. Kurtosis (Bayesian) | 67% | 50% | 39% | 37% |
| | | E | | |
| Treatment group (High b-values) | week1 | week2 | week3 | week4 |
| Treatment group (High b-values) Stretched vs. Mono | week1 97% | week2 99% | week3 99% | week4 100% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono | week1 97% 98% | week2 99% 99% | week3 99% 99% | week4 100% 99% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono | week1 97% 98% 95% | week2 99% 99% 99% | week3 99% 99% 98% | week4 100% 99% 98% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched | week1 97% 98% 95% 89% | week2 99% 99% 99% 78% | week3 99% 99% 98% 75% | week4 100% 99% 98% 71% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched | week1 97% 98% 95% 89% 86% | week2 99% 99% 99% 78% 40% | week3 99% 99% 98% 75% 83% | week4 100% 99% 98% 71% 72% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis | week1 97% 98% 95% 89% 86% 28% | week2 99% 99% 99% 78% 40% 16% | week3 99% 99% 98% 75% 83% 49% | week4 100% 99% 98% 71% 72% 56% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis Stretched (Bayesian) vs. Mono | week1 97% 98% 95% 89% 86% 28% 48% | week2 99% 99% 99% 78% 40% 16% 37% | week3 99% 99% 98% 75% 83% 49% | week4 100% 99% 98% 71% 72% 56% 8% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis Stretched (Bayesian) vs. Mono Kurtosis (Bayesian) vs. Mono | week1 97% 98% 95% 89% 86% 28% 48% 24% | week2 99% 99% 99% 78% 40% 16% 37% 26% | week3 99% 99% 98% 75% 83% 49% 6% 4% | week4 100% 99% 98% 71% 72% 56% 8% 4% |
| Treatment group (High b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis Stretched (Bayesian) vs. Mono Kurtosis (Bayesian) vs. Mono Biexp (Bayesian) vs. Mono | week1 97% 98% 95% 89% 86% 28% 48% 24% 99% | week2 99% 99% 78% 40% 16% 37% 26% 100% | week3 99% 98% 75% 83% 49% 6% 4% 100% | week4 100% 99% 98% 71% 72% 56% 8% 4% 98% |
| Treatment group (High b-values)Stretched vs. MonoKurtosis vs. MonoBiexp vs. MonoKurtosis vs. StretchedBiexp vs. StretchedBiexp vs. KurtosisStretched (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoBiexp (Bayesian) vs. MonoKurtosis (Bayesian) vs. Stretched (Bayesian) | week1 97% 98% 95% 89% 86% 28% 48% 24% 99% 34% | week2 99% 99% 99% 78% 40% 16% 37% 26% 100% 55% | week3 99% 98% 75% 83% 49% 6% 4% 100% 41% | week4 100% 99% 98% 71% 72% 56% 8% 4% 98% 70% |
| Treatment group (High b-values)Stretched vs. MonoKurtosis vs. MonoBiexp vs. MonoKurtosis vs. StretchedBiexp vs. StretchedBiexp vs. KurtosisStretched (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoBiexp (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoKurtosis (Bayesian) vs. Stretched (Bayesian)Biexp (Bayesian) vs. Stretched (Bayesian) | week1 97% 98% 95% 89% 86% 28% 48% 24% 99% 34% 80% | week2 99% 99% 99% 78% 40% 16% 37% 26% 100% 55% 51% | week3 99% 98% 75% 83% 49% 6% 4% 100% 41% 77% | week4 100% 99% 98% 71% 72% 56% 8% 4% 98% 70% 67% |

High b-value DWI data sets: Selection of preferred model in different groups, each comparing two models. Percentage of ROIs described better by the first model of the comparison is shown in the table.

| Control group (Low b-values) | week1 | week2 | week3 | week4 |
|--|---|---|---|---|
| Stretched vs. Mono | 79% | 70% | 71% | 81% |
| Kurtosis vs. Mono | 77% | 61% | 64% | 57% |
| Biexp vs. Mono | 68% | 41% | 46% | 77% |
| Kurtosis vs. Stretched | 19% | 23% | 29% | 12% |
| Biexp vs. Stretched | 29% | 11% | 10% | 40% |
| Biexp vs. Kurtosis | 51% | 30% | 29% | 71% |
| Stretched (Bayesian)vs. Mono | 47% | 18% | 21% | 25% |
| Kurtosis (Bayesian) vs. Mono | 8% | 16% | 13% | 9% |
| Biexp (Bayesian) vs. Mono | 43% | 17% | 12% | 42% |
| Kurtosis (Bayesian) vs. Stretched (Bayesian) | 21% | 26% | 34% | 22% |
| Biexp (Bayesian) vs. Stretched (Bayesian) | 37% | 41% | 21% | 50% |
| Biexp (Bayesian) vs. Kurtosis (Bayesian) | 62% | 49% | 37% | 62% |
| | | and the second se | and the second se | |
| Treatment group (Low b-values) | week1 | week2 | week3 | week4 |
| Treatment group (Low b-values) Stretched vs. Mono | week1 78% | week2 70% | week3 46% | week4 39% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono | week1 78% 79% | week2 70% 66% | week3 46% 55% | week4 39% 22% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono | week1 78% 79% 64% | week2 70% 66% 63% | week3 46% 55% 21% | week4 39% 22% 16% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched | week1 78% 79% 64% 18% | week2 70% 66% 63% 23% | week3 46% 55% 21% 66% | week4 39% 22% 16% 17% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched | week1 78% 79% 64% 18% 5% | week2 70% 66% 63% 23% 31% | week3 46% 55% 21% 66% 7% | week4 39% 22% 16% 17% 1% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis | week1 78% 79% 64% 18% 5% 33% | week2 70% 66% 63% 23% 31% 57% | week3 46% 55% 21% 66% 7% 10% | week4 39% 22% 16% 17% 1% 9% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis Stretched (Bayesian) vs. Mono | week1 78% 79% 64% 18% 5% 33% 49% | week2 70% 66% 63% 23% 31% 57% 37% | week3 46% 55% 21% 66% 7% 10% 6% | week4 39% 22% 16% 17% 1% 9% 8% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis Stretched (Bayesian) vs. Mono Kurtosis (Bayesian) vs. Mono | week1 78% 79% 64% 18% 5% 33% 49% 24% | week2 70% 66% 63% 23% 31% 57% 37% 25% | week3 46% 55% 21% 66% 7% 10% 6% 4% | week4 39% 22% 16% 17% 1% 9% 8% 4% |
| Treatment group (Low b-values) Stretched vs. Mono Kurtosis vs. Mono Biexp vs. Mono Kurtosis vs. Stretched Biexp vs. Stretched Biexp vs. Stretched Biexp vs. Kurtosis Stretched (Bayesian) vs. Mono Kurtosis (Bayesian) vs. Mono Biexp (Bayesian) vs. Mono | week1 78% 79% 64% 18% 5% 33% 49% 24% 26% | week2 70% 66% 63% 23% 31% 57% 37% 25% 20% | week3 46% 55% 21% 66% 7% 10% 6% 4% 6% | week4 39% 22% 16% 17% 1% 9% 8% 4% 4% |
| Treatment group (Low b-values)Stretched vs. MonoKurtosis vs. MonoBiexp vs. MonoKurtosis vs. StretchedBiexp vs. StretchedBiexp vs. KurtosisStretched (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoBiexp (Bayesian) vs. MonoKurtosis (Bayesian) vs. Stretched (Bayesian) | week1 78% 79% 64% 18% 5% 33% 49% 24% 24% 34% | week2 70% 66% 63% 23% 31% 57% 37% 25% 20% 55% | week3 46% 55% 21% 66% 7% 10% 6% 4% 6% 4% 6% 41% | week4 39% 22% 16% 17% 1% 9% 8% 8% 4% 4% 70% |
| Treatment group (Low b-values)Stretched vs. MonoKurtosis vs. MonoBiexp vs. MonoKurtosis vs. StretchedBiexp vs. StretchedBiexp vs. KurtosisStretched (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoBiexp (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoKurtosis (Bayesian) vs. MonoBiexp (Bayesian) vs. Stretched (Bayesian)Biexp (Bayesian) vs. Stretched (Bayesian) | week1 78% 79% 64% 18% 5% 33% 49% 24% 26% 34% 17% | week2 70% 66% 23% 31% 57% 37% 25% 20% 55% 23% | week3 46% 55% 21% 66% 7% 10% 6% 4% 6% 4% 6% 41% 26% | week4 39% 22% 16% 17% 1% 9% 8% 4% 4% 4% 70% 13% |

Low b-value DWI data sets: Selection of preferred model in different groups, each comparing two models. Percentage of ROIs described better by the first model of the comparison is shown in the table.

Proc. Intl. Soc. Mag. Reson. Med. 24 (2016) 3487